Imunon (NASDAQ:IMNN – Get Free Report) was upgraded by EF Hutton Acquisition Co. I to a “strong-buy” rating in a report issued on Monday, Zacks.com reports.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Imunon in a research note on Thursday, August 15th.
Imunon Price Performance
Imunon (NASDAQ:IMNN – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04. Sell-side analysts expect that Imunon will post -1.71 EPS for the current fiscal year.
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Articles
- Five stocks we like better than Imunon
- 5 discounted opportunities for dividend growth investors
- Why Small-Cap Stocks Could Be Ready to Outperform After Rate Cuts
- What is the Euro STOXX 50 Index?
- FedEx Stock Dips: Why Analysts See a Quick Rebound Coming
- What Are the FAANG Stocks and Are They Good Investments?
- PayPal Soars to New Heights: Why Analysts See More Upside
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.